Our Pipeline

AZEDRA® (iobenguane I 131) is a radiotherapeutic for unresectable, locally advanced or metastatic pheochromocytoma and paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.  AZEDRA was approved by the FDA on July 30, 2018 for the treatment in the U.S. of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. MORE>

RELISTOR^® subcutaneous injection, a small-molecule mu-opioid receptor antagonist, is approved in the United States for the treatment of opioid induced constipation in adult patients with chronic non-cancer pain. Progenics has licensed Relistor^® to Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Bausch Health Companies, Inc. in markets worldwide.

RELISTOR^® Tablets (methylnaltrexone bromide) is approved in the U.S. for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. Progenics has licensed Relistor^® to Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Bausch Health Companies, Inc. in markets worldwide.

PyL (also known as 18F-DCFPyL) is a fluorinated PSMA-targeted Positron Emission Topography (“PET”) imaging agent that enables visualization of both bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. MORE>

1404 is a PSMA-targeted small molecule SPECT/CT imaging agent labeled with technetium-99m that is designed to visualize both bone and soft tissue metastases. Rotop Pharmaka GmbH has been granted an exclusive license to development and commercialization of 1404 in Europe. 

1095 is a PSMA-targeted Iodine-131 labeled small molecule that is designed to deliver a dose of beta radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues. MORE>

PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic. The PSMA TTC is designed to deliver a dose of alpha radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues. Progenics has granted Bayer exclusive worldwide rights to develop and commercialize products using our PSMA antibody technology in combination with Bayer’s alpha-emitting radionuclides.

PSMA AI is an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA-targeted imaging.

Leronlimab (PRO 140) is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including NASH. It was sold to CytoDyn and, pursuant to our agreement with CytoDyn, we have the right to receive certain milestone and royalty payments.  MORE >